E
Avenir Wellness Solutions, Inc.
AVRW
$0.03
-$0.003-9.09%
E
Sell
2/5/2024Upgraded
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to E+ from E on 2/5/2024 due to an increase in the volatility index and valuation index.
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to E+ from E on 2/5/2024 due to an increase in the volatility index and valuation index.
E
Sell
1/19/2024Downgrade
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E from E+ on 1/19/2024 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0138 to -$0.0308.
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E from E+ on 1/19/2024 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0138 to -$0.0308.
E
Sell
3/14/2023Downgrade
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E+ from D on 03/14/2023.
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to D from E+ on 02/09/2023.
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E+ from D on 02/08/2023.
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E+ from D on 02/08/2023.
D
Sell
11/23/2022Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 11/23/2022 due to a major increase in the growth index, valuation index and volatility index. Earnings per share increased from -$0.14 to -$0.0508, and total revenue increased 58.86% from $1.12M to $1.78M.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 11/23/2022 due to a major increase in the growth index, valuation index and volatility index. Earnings per share increased from -$0.14 to -$0.0508, and total revenue increased 58.86% from $1.12M to $1.78M.
D
Sell
9/6/2022Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 9/6/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 1.35 to 4.65, the quick ratio declined from 0.04 to 0.02, and earnings per share declined from -$0.1013 to -$0.14.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 9/6/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 1.35 to 4.65, the quick ratio declined from 0.04 to 0.02, and earnings per share declined from -$0.1013 to -$0.14.
D
Sell
5/16/2022Upgraded
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to D from E+ on 05/16/2022.
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and valuation index.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and valuation index.
D
Sell
4/21/2022Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
E
Sell
4/20/2022Downgrade
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E+ from D on 04/20/2022.
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E+ from D on 04/20/2022.
D
Sell
4/18/2022Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 4/18/2022 due to a large increase in the growth index. EBIT increased 25.96% from -$4.34M to -$3.21M, total revenue increased 18.91% from $1.36M to $1.62M, and operating cash flow increased 17.05% from -$2M to -$1.66M.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 4/18/2022 due to a large increase in the growth index. EBIT increased 25.96% from -$4.34M to -$3.21M, total revenue increased 18.91% from $1.36M to $1.62M, and operating cash flow increased 17.05% from -$2M to -$1.66M.
D
Sell
11/17/2021Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 11/17/2021 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 278.73% from $1.12M to -$2M, earnings per share declined from -$0.0221 to -$0.07, and the quick ratio declined from 0.11 to 0.02.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 11/17/2021 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 278.73% from $1.12M to -$2M, earnings per share declined from -$0.0221 to -$0.07, and the quick ratio declined from 0.11 to 0.02.
D
Sell
11/9/2021Upgraded
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to D from E+ on 11/09/2021.
Avenir Wellness Solutions, Inc. (AVRW) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index.
D
Sell
11/3/2021Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 11/3/2021 due to an increase in the volatility index and total return index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 11/3/2021 due to an increase in the volatility index and total return index.
D
Sell
10/8/2021Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 10/8/2021 due to a decline in the volatility index.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 10/8/2021 due to a decline in the volatility index.
D
Sell
9/20/2021Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 9/20/2021 due to an increase in the volatility index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 9/20/2021 due to an increase in the volatility index.
D
Sell
9/2/2021Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 9/2/2021 due to a decline in the volatility index and total return index.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 9/2/2021 due to a decline in the volatility index and total return index.
D
Sell
8/18/2021Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 8/18/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 163.04% from -$1.78M to $1.12M, earnings per share increased from -$0.07 to -$0.0221, and total revenue increased 45.95% from $1.45M to $2.11M.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 8/18/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 163.04% from -$1.78M to $1.12M, earnings per share increased from -$0.07 to -$0.0221, and total revenue increased 45.95% from $1.45M to $2.11M.
D
Sell
7/19/2021Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 7/19/2021 due to a decline in the total return index and volatility index.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 7/19/2021 due to a decline in the total return index and volatility index.
D
Sell
7/1/2021Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 7/1/2021 due to an increase in the volatility index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 7/1/2021 due to an increase in the volatility index.
D
Sell
6/16/2021Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 6/16/2021 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.13 to 0.05, and EBIT declined 12.71% from -$4.58M to -$5.16M.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to D- from D on 6/16/2021 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 0.13 to 0.05, and EBIT declined 12.71% from -$4.58M to -$5.16M.
D
Sell
4/13/2018Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 4/13/2018 due to an increase in the volatility index, total return index and valuation index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D from D- on 4/13/2018 due to an increase in the volatility index, total return index and valuation index.
D
Sell
3/27/2018Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D- from E+ on 3/27/2018 due to an increase in the valuation index and solvency index.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D- from E+ on 3/27/2018 due to an increase in the valuation index and solvency index.
E
Sell
2/21/2018Downgrade
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D- on 2/21/2018 due to a substantial decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.16 to 0.06.
CURE Pharmaceutical Holding Corp. (CURR) was downgraded to E+ from D- on 2/21/2018 due to a substantial decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.16 to 0.06.
D
Sell
10/2/2017Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D- from E on 10/2/2017 due to an increase in the growth index and valuation index. Total revenue increased 21.94% from $31.9 to $38.9, EBIT increased 8.55% from -$2.63M to -$2.4M, and earnings per share increased from -$0.1123 to -$0.1084.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to D- from E on 10/2/2017 due to an increase in the growth index and valuation index. Total revenue increased 21.94% from $31.9 to $38.9, EBIT increased 8.55% from -$2.63M to -$2.4M, and earnings per share increased from -$0.1123 to -$0.1084.
E
Sell
7/5/2017Upgraded
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to E from E- on 7/5/2017 due to a significant increase in the total return index, growth index and solvency index. Total revenue increased 66.15% from $19.2 to $31.9, and operating cash flow increased 22.8% from -$772.2 to -$596.1.
CURE Pharmaceutical Holding Corp. (CURR) was upgraded to E from E- on 7/5/2017 due to a significant increase in the total return index, growth index and solvency index. Total revenue increased 66.15% from $19.2 to $31.9, and operating cash flow increased 22.8% from -$772.2 to -$596.1.
E
Sell
4/18/2017None
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E- from U on 04/18/2017.
Avenir Wellness Solutions, Inc. (AVRW) was downgraded to E- from U on 04/18/2017.
OTC PK
03/07/2025 3:25PM Eastern
Quotes delayed
